WHAT'S NEW
The recently published data of three randomized controlled trials in the New England Journal of Medicine demonstrated that PFO closure plus medical therapy reduces the risk of recurrent stroke in cryptogenic patients versus medical therapy alone. In light of the new studies, this activity discusses how to create a PFO closure program and how to provide referring physicians with clarity on the procedure and clinical data. WATCH
Image Review
 Daniel H. Steinberg, MD reviews the case of an 89-year-old patient with a history of chronic systolic heart failure. REVIEW
CMS IPPS Proposed Rule Integrates Newer SHD Procedures, as Recommended by SCAI
On June 16, SCAI submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding the 2016 Inpatient Prospective Payment (IPPS) System proposed rule, which would create new diagnosis-related groups (DRGs) for intra-cardiac procedures, including several structural heart disease (SHD) procedures. The proposed rule reflects SCAI's earlier recommendations, which urged CMS to establish a new DRG for SHD procedures not captured by the 2015 Proposed Endovascular/Transcatheter Cardiac Valve DRG. READ SCAI'S COMMENTS TO CMS
Image Review
 Review the case of an elderly patient with severe symptomatic aortic stenosis with Daniel H. Steinberg, MD. LAUNCH
FDA Approves SAPIEN 3 THV Artificial Heart Valve
FDA: On June 17, the U.S. Food and Drug Administration today approved the SAPIEN 3 Transcatheter Heart Valve (THV) for patients with a narrowing in the heart's aortic valve, called aortic valve stenosis. The SAPIEN 3 THV is approved for patients with aortic valve stenosis who are inoperable or at high risk for death or complications associated with open-heart surgery. ADDITIONAL INFORMATION
|